Children with CKD have a significant burden, including fatigue and sleep disturbances.

Published Date: 13 Mar 2023

A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...

Read Full News

Latest News

Deep Dive: The Evolving GLP-1 Class Overview

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

First-in-Class Drug Approved for IgA Nephropathy

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Navigating New Guidelines in IgA Nephropathy

FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

Todays Updates

An Oral Ketamine Drug for Depression — Minus the Trip?

A novel oral ketamine drug shows a signal for reducing depressive symptoms with minimal dissociative effects.

Info on Risk for Prostate Cancer Spurs Decision-Making

Men who receive personalized estimates of the likelihood of raised prostate-specific antigen levels are more likely to decide to get screening than those who receive general information on pros and cons.

Fast Symptom Relief in Ulcerative Colitis: Which Rx Wins?

Upadacitinib and infliximab offer rapid relief from symptoms in biologic-naive patients with moderate-to-severe ulcerative colitis.

Europe’s AI Reality: Practice Outpaces Policy and Reviews

Clinicians and patients are already relying on AI, while hospitals are still building the oversight to keep up.

Cognitive Benefit of Healthy Living Confirmed: LatAm-FINGERS

A culturally tailored lifestyle program improves cognition significantly more than standard health advice among older adults at risk for dementia across Latin America.

Health Issues Tied to Behaviours in Intellectual Disability

People with intellectual disabilities who have physical health problems or sensory impairments face a higher risk for challenging behaviours.

Rimegepant Effective in Treatment-Resistant Migraine

Rimegepant is safe and effective in patients with migraine not responding to multiple prior preventive therapies, a real-world study shows.

Todays Updates

An Oral Ketamine Drug for Depression — Minus the Trip?

A novel oral ketamine drug shows a signal for reducing depressive symptoms with minimal dissociative effects.

Info on Risk for Prostate Cancer Spurs Decision-Making

Men who receive personalized estimates of the likelihood of raised prostate-specific antigen levels are more likely to decide to get screening than those who receive general information on pros and cons.

Fast Symptom Relief in Ulcerative Colitis: Which Rx Wins?

Upadacitinib and infliximab offer rapid relief from symptoms in biologic-naive patients with moderate-to-severe ulcerative colitis.

Europe’s AI Reality: Practice Outpaces Policy and Reviews

Clinicians and patients are already relying on AI, while hospitals are still building the oversight to keep up.

Cognitive Benefit of Healthy Living Confirmed: LatAm-FINGERS

A culturally tailored lifestyle program improves cognition significantly more than standard health advice among older adults at risk for dementia across Latin America.

Health Issues Tied to Behaviours in Intellectual Disability

People with intellectual disabilities who have physical health problems or sensory impairments face a higher risk for challenging behaviours.

Rimegepant Effective in Treatment-Resistant Migraine

Rimegepant is safe and effective in patients with migraine not responding to multiple prior preventive therapies, a real-world study shows.

Latest News

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

News All Time

APOL1 Gene and Focal Segmental Glomerulosclerosis

Genetic variants tied to increased risk are only found in those of African decent

Make the Diagnosis: Chest Pain, Dyspnea, Palpitations, and More: What’s Her Diagnosis?

A 45-year-old woman presented to the emergency department with complaints of chest pain, heart palpitations that developed earlier that day, and dyspnea that began 3 days prior and had progressed. Can you diagnose the patient?

Rewriting What We Know About Kidney Transplant Rejection

Rewriting What We Know About Kidney Transplant Rejection

First Oral Carbapenem Approved for Complicated UTIs

Tebipenem pivoxil proved noninferior to IV imipenem-cilastatin in hospitalized patients

How Did a Patient Survive a Decade With Metastatic RCC?

Surgery had beneficial role

360 Dead in Outbreak; McConnell Still Hospitalized? FDA Rejects Kidney Disease Drug

Health news and commentary gathered by MedPage Today staff

US FDA Declines to Approve Unicycive's Kidney Disease Drug

Unicycive Therapeutics said on Tuesday the U.S. drug regulator has declined to approve its drug to ⁠treat elevated phosphate levels in chronic kidney disease patients on...

The Chatbot Will See You Now: A Crisis in Trust?

When healthcare feels out of reach, Europe’s patients are turning to AI for answers — and sometimes for the confidence to medicate themselves.

Extended-Release Febuxostat Beats Standard Drug for Gout

A new 24-hour version of febuxostat lowers uric acid levels significantly better than the standard drug for patients with severe gout, though it may carry a higher risk of serious side effects.

Mineralys' Pill Cuts Blood Pressure in Kidney Disease Patients

Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chronic kidney disease, according to new data presented ⁠at a major European...

Project Aims for Awareness of APOL1-Mediated Kidney Disease

The EMBARK Awareness initiative is working to raise awareness of APOL-1 mediated kidney disease among high-risk populations and medical trainees.

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Recommended News For You

Advances in "next generation" photoactive cancer therapy

Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx

FDA Approves New Drug Combo for RR Multiple Myeloma

Early breast cancer detection may be possible with a wearable ultrasound scanner.

Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer

FDA approves rivanetin as the first-line treatment for lung cancer.

The self-sacrificing nature of breast cancer cells has been identified as a possible reason for relapse.

Recommended Articles For You

AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency 

Hematologic Cytomorphology: From Microscopy to Molecular Diagnostics 

Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment 

Cancer Vaccines In India: The Latest Hope In The Fight Against Disease 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain

2.

In prostate cancer survivorship, sleep disturbances are underappreciated.

3.

How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma

4.

Breast Cancer Genetic Testing Need in Black Women Identified

5.

Drugmaker Pulls Trodelvy's Bladder Cancer Approval

1.

Seeing the Unseen: The Benefits of Early Stage Breast Cancer Ultrasound

2.

Exploring the Mystery of Angiokeratomas on Scrotum: Causes, Symptoms and Treatment

3.

The Ins and Outs of Glossectomy: What You Need to Know 

4.

Understanding Hidrocystoma: Symptoms, Causes, and Treatment Options 

5.

Understanding Neutrophilia: Causes, Symptoms, and Treatment Options

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

2.

Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment

3.

Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

5.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot